Welcome to our dedicated page for Pharvaris news (Ticker: PHVS), a resource for investors and traders seeking the latest updates and insights on Pharvaris stock.
Pharvaris N.V. reports developments as a late-stage biopharmaceutical company developing oral bradykinin B2 receptor antagonists for bradykinin-mediated diseases, including hereditary angioedema and acquired angioedema due to C1 inhibitor deficiency. Its lead program, deucrictibant, is being developed in immediate-release capsule and extended-release tablet forms for on-demand and prophylactic treatment settings.
Recurring updates include clinical data from the RAPIDe and CHAPTER study programs, patient-reported outcome research, scientific publications, presentations at allergy and immunology meetings, financial results, strategic priorities, shareholder voting matters and capital-structure disclosures.
Pharvaris (Nasdaq: PHVS) published a peer-reviewed study validating patient-reported outcome (PRO) instruments for on-demand hereditary angioedema (HAE) treatment endpoints.
The non-interventional, mixed-methods study found PGI and AMRA tools reliable and sensitive, identified End of Progression™ as earliest meaningful endpoint, and aligned PGI-C "a little better" with AMRA-3 ≥20%, informing Phase 3 RAPIDe-3 endpoint hierarchy.
Pharvaris (Nasdaq: PHVS) presented Phase 3 RAPIDe-3 and Phase 2 CHAPTER-1 data at AAAAI 2026 supporting deucrictibant for on‑demand and prophylactic treatment of bradykinin‑mediated angioedema.
RAPIDe-3 met the primary and all 11 secondary endpoints: median onset of symptom relief 1.28 hours and complete resolution 11.95 hours versus much longer placebo times. CHAPTER-1 OLE showed mean attack rate fell from 2.18 to 0.12 attacks/month and roughly half of participants were attack free; no treatment‑related serious adverse events reported.
Pharvaris (Nasdaq: PHVS) will present six abstracts, including three Featured Posters, at the AAAAI 2026 Annual Meeting in Philadelphia from February 27–March 2, 2026. Key topics include pivotal Phase 3 RAPIDe-3 on-demand data, final CHAPTER-1 open-label results, and extended-release pharmacokinetics for CHAPTER-3.
Topline CHAPTER-3 results are anticipated in Q3 2026. Posters and slides will be posted on the company's investor site at the start of each presentation.
Pharvaris (NASDAQ: PHVS) outlined 2026 priorities focused on late‑stage development and regulatory filings for oral deucrictibant for bradykinin‑mediated angioedema. Key milestones: topline CHAPTER‑3 prophylaxis data expected 3Q2026; NDA preparation for on‑demand HAE treatment targeted for filing in 1H2026 based on RAPIDe‑3 and RAPIDe‑2; RAPIDe‑3 met its primary and all secondary endpoints with median onset of symptom relief of 1.28 hours (p<0.0001). CREAATE pivotal study in AAE‑C1INH is enrolling; CHAPTER‑4 long‑term extension is ongoing; CHAPTER‑1 open‑label data showed mean on‑treatment monthly attack rate of 0.12. Corporate runway is estimated into 1H2027, and Pharvaris was added to the Nasdaq Biotechnology Index in Dec 2025.
Pharvaris (NASDAQ: PHVS) reported positive topline results from the RAPIDe-3 pivotal Phase 3 study of oral deucrictibant IR 20 mg for on-demand treatment of hereditary angioedema (HAE) attacks.
The primary endpoint was met: median time to onset of symptom relief was 1.28 hours vs >12 hours for placebo (p<0.0001). All 11 secondary endpoints were significant, including End of Progression™ 17.47 minutes/b vs 228.67 minutes and median time to complete symptom resolution Deucrictibant was well tolerated with no treatment-related serious adverse events; NDA filings are planned starting H1 2026.
Pharvaris (Nasdaq: PHVS) reported Q3 2025 results and a business update highlighting pivotal Phase 3 programs for deucrictibant. RAPIDe-3 (on-demand HAE, 20 mg immediate-release) reached ~120 participants and topline data are expected in 4Q2025. CHAPTER-3 (prophylaxis, 40 mg extended-release) enrollment is progressing with topline data anticipated in 2H2026. Pharvaris initiated CREAATE (AAE-C1INH pivotal study) and reported Phase 2 CHAPTER-1 OLE on-treatment attack rate of 0.12. Corporate financing included a public offering with proceeds of approximately $201 million. Cash and cash equivalents were €329 million as of September 30, 2025, providing runway into H1 2027. Q3 operating metrics: R&D €29.8M, G&A €9.8M, net loss €37.1M (loss per share €0.60).
Pharvaris (Nasdaq: PHVS) presented clinical and biomarker data at ACAAI 2025 highlighting deucrictibant's long-term safety, sustained efficacy, and a validated kinin assay.
Key data: open-label CHAPTER-1 extension showed treatment for up to ~34 months with mean attacks reduced from 2.18 to 0.12 attacks/month and an average 92.4% attack reduction; RAPIDe-2 Part A reported a median time-to-onset of symptom relief of 1.1 hours and median time-to-resolution of 10.6 hours with 89.2% of attacks resolved at 24 hours after a single dose.
The company also reported a clinically validated plasma kinin biomarker assay and reiterated expected pivotal readouts: CHAPTER-3 in H2 2026 and RAPIDe-3 in Q4 2025.
Pharvaris (Nasdaq: PHVS) announced acceptance of 2 oral and 6 poster presentations at the American College of Allergy, Asthma, and Immunology (ACAAI) 2025 Annual Scientific Meeting in Orlando, November 6–10, 2025.
Presentations focus on clinical data for oral deucrictibant in hereditary angioedema (prophylaxis and on‑demand treatment), biomarker assay validation, long‑term safety and efficacy (CHAPTER‑1 and RAPIDe‑2), and pharmacokinetics of an extended‑release tablet. Slides and posters will be posted on the company's investor website at presentation start times.
Pharvaris (NASDAQ:PHVS) reported Q2 2025 financial results and provided significant pipeline updates for its oral bradykinin B2 receptor antagonist programs. The company anticipates topline results from RAPIDe-3, a pivotal Phase 3 study for HAE attack treatment, in Q4 2025. Enrollment continues in CHAPTER-3, another Phase 3 study for HAE attack prophylaxis, with results expected in 2H 2026.
The company strengthened its financial position with €200 million in cash as of June 30, 2025, and subsequently raised $201 million through a public offering, extending its cash runway into 1H 2027. Q2 2025 financial results showed R&D expenses of €29.6 million and a net loss of €45.5 million (€0.83 per share).
[ "Successful $201 million public offering extends cash runway into 1H 2027", "Multiple Phase 3 trials progressing on schedule with RAPIDe-3 results expected in Q4 2025", "Strong cash position of €200 million as of June 30, 2025", "Pipeline expansion into additional indications including AAE-C1INH" ]Pharvaris (NASDAQ:PHVS), a late-stage biopharmaceutical company, has successfully closed its upsized public offering, raising $201.2 million in gross proceeds. The offering included 9,562,500 ordinary shares (including the full exercise of underwriters' option for 1,312,500 additional shares) and pre-funded warrants to purchase 500,000 ordinary shares.
The offering was managed by a syndicate of investment banks including Morgan Stanley, Leerink Partners, Cantor, Oppenheimer & Co., and Van Lanschot Kempen as joint book-running managers. The securities were offered through an effective shelf registration statement previously filed with the SEC.